Related Experiment Video
Updated: Jun 23, 2026

Isolation and Physiological Analysis of Mouse Cardiomyocytes
Published on: September 7, 2014
Myocardial catecholamines in primary heart muscle disease: fact or fancy?
P M Seferović1, R Maksimović, M Ostojić
1Institute for Cardiovascular Disease, University Medical Centre, Belgrade, Yugoslavia.
Insights
Patients with hypertrophic cardiomyopathy (HCM) show significantly higher myocardial norepinephrine and epinephrine concentrations compared to dilated cardiomyopathy (DCM). These findings shed light on catecholamine roles in heart muscle diseases.
Area of Science:
- Cardiology
- Biochemistry
- Pathophysiology
Background:
- The role of myocardial catecholamines in cardiomyopathies remains incompletely understood.
- Catecholamines are crucial neurotransmitters and hormones affecting cardiac function.
Purpose of the Study:
- To assess and compare myocardial catecholamine concentrations (MCC) in patients with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
- To investigate potential differences in MCC across various etiologies of DCM.
Main Methods:
- Endomyocardial biopsy samples were obtained from 34 HCM patients and 32 DCM patients.
- Myocardial norepinephrine (MNEC), epinephrine (MEC), and dopamine (MDC) concentrations were measured using the catechol-O-methyl transferase radioenzymatic method.
- MCC levels were also compared among different etiological subgroups of DCM.
Main Results:
- Significantly higher MNEC and MEC were observed in HCM patients compared to DCM patients (p < 0.01).
- No statistically significant difference was found in MDC levels between HCM and DCM groups (p > 0.05).
- No significant differences in MCC were found among primary DCM, alcohol-induced heart disease, and hypertensive heart disease subgroups.
Conclusions:
- Myocardial norepinephrine and epinephrine levels are significantly elevated in HCM compared to DCM.
- Catecholamine levels do not significantly differ across various etiologies of dilated cardiomyopathy.
- Further research is warranted to elucidate the precise pathophysiological role of myocardial catecholamines in different cardiomyopathies.
Abstract:
The pathophysiological role of myocardial catecholamines in cardiomyopathies is still not completely understood. We there-fore assessed myocardial catecholamine concentrations (MCC) in 34 patients with hypertrophic cardiomyopathy (HCM) (76.5% males; mean age 46.7 +/- 11.6 years; left ventricular ejection fraction [LVEF] 75.3 +/- 9.8%) and in 32 patients with dilated cardiomyopathy (DCM) (87.5% males, mean age 43.1 +/- 12.5 years, LVEF 34.9 +/- 8.3%). Initial assessment included clinical work up, cardiac catheterization and endomyocardial biopsy. Myocardial norepinephrine (MNEC), epinephrine (MEC), and dopamine (MDC) concentrations in endomyocardial biopsy samples were measured using the catechol-O- methyl transferase radioenzymatic method. Significantly higher MNEC and MEC were demonstrated in HCM than in DCM patients (MNEC: 781.9 +/- 125.8 ng.g-1 fresh myocardial tissue (ft) HCM vs 262.6 +/- 68.9 ng.g-1 ft DCM, p < 0.01; and MEC: 91.6 +/- 13.9 ng.g-1 ft HCM vs 35.8 +/- 6.2 ng.g-1 ft DCM, P < 0.01). The difference in MDC did not reach statistical significance (76.1 +/- 8.3 ng.g-1 ft HCM vs 70.1 +/- 11.8 ng.g ft DCM; P > 0.05). In addition, we compared the MCC levels in 24 patients, clinically presented as dilated cardiomyopathy categorized according to the various aetiologies: 12/24 with primary DCM (75.0% males, mean age 49.6 +/- 9.5 years; LVEF 25.8 +/- 63%), 7/24 with alcohol-induced heart disease (85.7% males, mean age 46.8 +/- 7.1 years; LVEF 26.4 +/- 4.6%), and 5/24 with hypertensive heart disease (100% males, 45.1 +/- 10.6 years; LVEF 25.6 +/- 9.1%), but no significant difference was found among them (P > 0.05). There was no significant difference in tissue dopamine concentrations.
Related Concept Videos
Pathophysiology of Cardiac Performance
Heart Failure Drugs: Inotropic Agents
Myocarditis I: Introduction
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy

